Chaperone-rich cell lysate (CRCL) (CRCL)

Chaperone-rich cell lysate (CRCL) is a therapeutic vaccine preparation derived from tumor cells that concentrates key heat shock proteins (HSPs)—specifically HSP70, HSP90, gp96, and calreticulin—along with their associated tumor-specific peptides (Graner et al., 2000). These HSPs serve as natural adjuvants and delivery vehicles that facilitate the efficient capture and cross-presentation of a broad spectrum of tumor antigens by dendritic cells (Srivastava, 2002). By utilizing the full repertoire of antigens present in a patient's tumor, CRCL aims to generate a polyvalent immune response that can overcome tumor heterogeneity and prevent immune escape (Zeng et al., 2003). Clinical investigations have focused on CRCL as an autologous or allogeneic immunotherapy for various cancers, including non-small cell lung cancer and melanoma (Senzer et al., 2007). The preparation leverages the innate stress-signaling properties of chaperones to enhance the visibility of malignant cells to the immune system (Calderwood et al., 2007). This approach represents a personalized strategy to induce robust, long-lasting anti-tumor T-cell activity.

Other names

HSP-peptide complexChaperone-rich lysateTumor-derived chaperone-rich cell lysateHSP70-HSP90-gp96-calreticulin complex

The mechanism of action involves the uptake of heat shock protein-peptide complexes (HSPPCs) by antigen-presenting cells (APCs) through receptors like CD91. Once internalized, the chaperoned tumor-derived peptides are processed and cross-presented on MHC class I and II molecules, leading to the activation of CD8+ and CD4+ T cells specific to the tumor antigens (Srivastava, 2002; Graner et al., 2000). Additionally, the HSP components (HSP70, HSP90, gp96, calreticulin) act as danger signals, promoting APC maturation and the secretion of pro-inflammatory cytokines (Calderwood et al., 2007).